contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  availableLanguages
  pageUrl
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


biotage-publishes-prospectus-for-admission-to-trading-of-shares-to-be-issued-as-part-of-the-acquisition-of-astrea-bioseparations-on-nasdaq-stockholm

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

availableLanguages

pageUrl

imgUrl

description

Biotage is active in biotechnology. The company provides solutions in chromatography, organic synthesis, and sample preparation. The company has operations on a global level, mainly concentrated in Europe, North America, and Asia, and a large part of the projects are also conducted in collaboration with other players in the said market. Customers are found in health and care, as well as in the food industry.

Biotage

Uppsala, Sweden – 30 May 2023 – As previously announced, Biotage AB (publ) (“Biotage”) has entered into agreements to acquire all of the shares in Astrea Bioseparations (“Astrea”) from Gamma...

<div class="mfn-body">Uppsala, Sweden – 30 May 2023 – As previously announced, Biotage AB (publ) (“Biotage”) has entered into agreements to acquire all of the shares in Astrea Bioseparations (“Astrea”) from Gamma Biosciences (“Gamma”) [1], a life sciences tools platform created by KKR. The acquisition also includes the shares held by certain minority investors [2] in the Astrea group (together with Gamma, the “Sellers”, and together with the acquisition of Astrea, the “Transaction”). The Transaction is expected to be completed on or around 1 June 2023. As part consideration for the Transaction, the board of directors of Biotage will, by virtue of an authorization granted by the Annual General Meeting held on 27 April 2023, resolve to issue 13,954,103 ordinary shares to the Sellers.A prospectus regarding admission to trading of the ordinary shares, to be issued as part of the Transaction, on Nasdaq Stockholm, has been approved and registered with the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and is available on the Company’s website, <a rel="noopener" href="http://www.biotage.com/">www.biotage.com</a>.About Biotage Biotage is a Global Impact Tech Company committed to solving society’s problems. We offer workflow solutions and products to customers in drug discovery and development and diagnostics, analytical testing and water and environmental testing.Biotage is contributing to sustainable science with the goal to make the world a healthier, greener and cleaner place – HumanKind Unlimited.Our customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research and contract manufacturers as well as clinical, forensic and academic laboratories in addition to organizations focused on food safety, clean water and environmental sustainability.Biotage is headquartered in Uppsala in Sweden and employs over 500 people worldwide. The Group had sales of 1,566 MSEK in 2022 and our products are sold in more than 80 countries. Biotage’s share (BIOT) is listed in the Large Cap segment on the NASDAQ Stockholm.Website: <a rel="noopener" href="http://www.biotage.com/">www.biotage.com</a>Contacts Tomas Blomquist, President and CEO Tel: 0705 23 01 63, <a rel="noopener" href="mailto:tomas.blomquist@biotage.com">tomas.blomquist@biotage.com</a>The information was submitted for publication, through the agency of the contact person set out above, at 2023-05-30 10:50 CEST.[1] Held through Gamma Biosciences Newco Limited and Gamma Biosciences Newco 2 Limited, two entities controlled by KKR. [2] Held through Nano Hold Co., LLC.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments<hr><a rel="noopener" href="https://storage.mfn.se/a019990a-0187-4472-ae7d-3b2731e357d0/biotage-publishes-prospectus-for-admission-to-trading-of-shares-to-be-issued-as-part-of-the-acquisition-of-astrea-bioseparations-on-nasdaq-stockholm.pdf" class="mfn-generated mfn-primary">Biotage publishes prospectus for admission to trading of shares, to be issued as part of the acquisition of Astrea Bioseparations, on Nasdaq Stockholm</a></div>

Biotage publishes prospectus for admission to trading of shares, to be issued as part of the acquisition of Astrea Bioseparations, on Nasdaq Stockholm

Pysy ajantasalla Inderesin uutiskirjeillä